Talecris Press Release

Grifols to Acquire Talecris Biotherapeutics Creating a World Leading Provider of Life-Saving Plasma Protein Therapies

Mon, 07 Jun 2010 9:00:00 EST

BARCELONA, Spain and RESEARCH TRIANGLE PARK, N.C., June 7, 2010 /PRNewswire via COMTEX/ --Grifols (GRF.MC) a global healthcare company and leading producer of plasma protein therapies, and Talecris (Nasdaq: TLCR) a U.S.-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an aggregate value today of approximately $3.4 billion (euro 2.8 billion), creating a global leader of life-saving and life enhancing plasma protein therapeutics.

Talecris Biotherapeutics Announces First Quarter 2010 Results

Wed, 28 Apr 2010 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., April 28, 2010 /PRNewswire via COMTEX/ --Talecris Biotherapeutics Holdings Corp. ("Talecris") (Nasdaq: TLCR) today announced its financial results for the three months ended March 31, 2010, and filed its first quarter 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting

Tue, 20 Apr 2010 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., April 20, 2010 /PRNewswire via COMTEX/ --Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) held its annual meeting of stockholders today in Chapel Hill, N.C. During the meeting, the stockholders elected Paul N. Clark and Kenneth J. Martin as Class I Directors to serve on the company's Board of Directors for three-year terms ending in 2013. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the company's independent public accounting firm for the fiscal year ending December 31, 2010.

Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations

Thu, 07 Jan 2010 9:00:00 EST

Research Triangle Park, NC (Jan. 7, 2010) -- Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) announced today the appointment of Drayton Virkler as senior director of the Talecris Investor Relations department.

Talecris Biotherapeutics Receives Health Canada Approval for PROLASTIN(R)-C

Wed, 17 Feb 2010 9:00:00 EST

Research Triangle Park, N.C. (Feb. 17, 2010) – Talecris Biotherapeutics (Nasdaq: TLCR) announced today that it has received approval from Health Canada for PROLASTIN(R)-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN(R) produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

Gamunex(R) is the Preferred IGIV Therapy of Neurologists

Mon, 12 Apr 2010 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., April 12, 2010 /PRNewswire via COMTEX/ --Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex(R) (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive(R) on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

Talecris Biotherapeutics to Present at the Goldman Sachs Leveraged Finance Healthcare Conference

Wed, 10 Mar 2010 9:00:00 EST

Talecris Biotherapeutics to Present at the Goldman Sachs Leveraged Finance Healthcare Conference

Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2009 Results

Tue, 23 Feb 2010 9:00:00 EST

Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2009 Results

Talecris Biotherapeutics Donates Vital Medical Treatment and Supplies to Haitian Relief Efforts

Mon, 15 Feb 2010 9:00:00 EST

Talecris Biotherapeutics Donates Vital Medical Treatment and Supplies to Haitian Relief Efforts

Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2009 Financial Results

Wed, 10 Feb 2010 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., Feb 10, 2010 (BUSINESS WIRE) -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) will release its fourth quarter and full year 2009 financial results on February 23, 2010, after the stock market closes, and will host a conference call at 8:30 AM Eastern Time on February 24, 2010.

Talecris Biotherapeutics Announces Record Date for 2010 Annual Meeting of Shareholders

Wed, 10 Feb 2010 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., Feb 10, 2010 (BUSINESS WIRE) -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) announced today that its Board of Directors established March 11, 2010 as the record date for determining stockholders entitled to vote at the 2010 Annual Meeting of Stockholders. The annual meeting will be held on April 20, 2010 at 9:00 AM Eastern Time at The Carolina Inn, 211 Pittsboro Street in Chapel Hill, North Carolina.

Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Alpha1-Proteinase Inhibitor to Treat Alpha1-Antitrypsin Deficiency

Fri, 05 Feb 2010 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., Feb 05, 2010 (BUSINESS WIRE) -- Talecris Biotherapeutics, Inc. (Nasdaq: TLCR) announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.

Dean Mitchell Appointed to Talecris Board of Directors

Thu, 17 Dec 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., Dec 17, 2009 (BUSINESS WIRE) -- Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) today announced that Dean Jonathan Mitchell has been appointed to its board of directors. Mitchell's appointment brings the number of Talecris board members to ten

Talecris Biotherapeutics Announces Third Quarter 2009 Results

Tue, 10 Nov 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov. 9, 2009-- Talecris Biotherapeutics Holdings Corp. (“Talecris”) (Nasdaq: TLCR) today announced its financial results for the three and nine months ended September 30, 2009 and filed its third quarter Form 10-Q today with the U.S. Securities and Exchange Commission (SEC). Third quarter 2009 net revenue increased by 12.9% to $395.7 million from $350.5 million in the third quarter of 2008. Diluted earnings per share were $0.38 in the third quarter of 2009, which is a 72.7% increase over diluted earnings per share of $0.22 for the third quarter of 2008. Total diluted shares outstanding were 93,911,201 for the third quarter of 2009 compared to diluted shares outstanding of 92,097,404 for the third quarter of 2008.

Talecris Biotherapeutics to Report Third Quarter 2009 Financial Results

Fri, 30 Oct 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 30, 2009-- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) will release its third quarter 2009 financial results on November 9, 2009, after the stock market closes, and will host a conference call at 8:30 AM Eastern Time on November 10, 2009.

Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C

Wed, 21 Oct 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C., Oct. 19 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN(R)-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN(R) produced using advances in manufacturing technology.

Talecris Announces Pricing of $600 Million Senior Notes due 2016

Fri, 16 Oct 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 16, 2009-- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) (“Talecris”) today announced the pricing through a private placement of $600 million aggregate principal amount of 7.75% senior notes due 2016 (the “Notes”). The Notes were issued at price of 99.321% of par. Talecris intends to use the net proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, extinguish certain interest rate swaps, and pay related fees and expenses. The offering is expected to close on or about October 21, 2009, subject to customary closing conditions.

The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc

Thu, 15 Oct 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, NC and MIAMI, FL (Oct. 13, 2009) —The Alpha-1 Foundation announced today that it has awarded two research grants to study how genetic variations in the alpha-1 antitrypsin (AAT) gene contribute to lung and liver damage in people with AAT deficiency. The inherited condition causes emphysema and liver disease. The research will also investigate whether AAT infusion therapy – known as augmentation therapy -- minimizes liver damage among individuals with AAT deficiency.

Talecris Biotherapeutics Announces Private Offering of $550 Million Senior Notes due 2016

Tue, 13 Oct 2009 9:00:00 EST

Research Triangle Park, N.C. (October 13, 2009) — Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) (“Talecris” or the “Company”) today announced that it has commenced an offering through a private placement of $550 million aggregate principal amount of senior notes due 2016 (the “Notes”). Talecris intends to use the proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, and to pay related fees and expenses.

Talecris Biotherapeutics Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

Wed, 07 Oct 2009 9:00:00 EST

Research Triangle Park, N.C. (October 7, 2009) — Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) (“Talecris” or the “Company”) today announced the closing on October 6 of its initial public offering of shares of common stock, which was priced on September 30 at a public offering price of $19.00 per share. In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional 6,000,000 shares of common stock from the selling stockholder, Talecris Holdings, LLC. Talecris Holdings LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and by limited partnerships affiliated with Ampersand Ventures. As a result, a total of 56,000,000 shares were sold in the initial public offering, consisting of 28,947,368 shares by the Company and 27,052,632 shares by the selling stockholder. Net proceeds received by the Company were used to pay down debt. The Company did not receive any proceeds from the sale of shares by the selling stockholder.

Talecris Prices Initial Public Offering of Common Stock at $19.00 Per Share

Wed, 30 Sep 2009 9:00:00 EST

Research Triangle Park, N.C. (September 30, 2009) — Talecris Biotherapeutics Holdings Corp. (“Talecris” or the “Company”) today announced the pricing of its initial public offering of 50,000,000 shares of its common stock at a price of $19.00 per share. Of the shares being offered, 28,947,368 are being offered by the Company and 21,052,632 are being offered by the selling stockholder, Talecris Holdings, LLC. Talecris Holdings, LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and limited partnerships affiliated with Ampersand Ventures. The underwriters have the option to purchase from the selling stockholder up to an additional 6,000,000 shares of common stock. The common stock is expected to begin trading on the Nasdaq Stock Market LLC on October 1, 2009 under the ticker symbol “TLCR.”

Talecris Commences Initial Public Offering of Common Stock

Tue, 15 Sep 2009 9:00:00 EST

Research Triangle Park, N.C. (September 15, 2009) — Talecris Biotherapeutics Holdings Corp. (“Talecris”) today announced the launch of its initial public offering of 44,736,842 shares of its common stock, par value $0.01 per share. Talecris is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, neurology, pulmonology and hemostasis.

Talecris Receives Orphan Drug Designation for Plasmin

Tue, 09 June 2009 9:00:00 EST

Talecris Biotherapeutics, Inc. today announced that it has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of Plasmin (Human) to treat acute peripheral arterial occlusion (PAO). Talecris is currently investigating Plasmin in a phase I/II clinical trial designed to assess its ability to treat PAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot. Currently, there are no FDA approved treatments for acute PAO.

Alpha-1 Foundation Announces the Million Dollar Match

Thu, 04 June 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C. and MIAMI, Fla.(June 4, 2009) — The Alpha-1 Foundation announced today it will receive up to $1 million in grant matching funds from Talecris Biotherapeutics, Inc. to support research into alpha₁-antitrypsin deficiency, a genetic condition in which low levels of the essential blood protein alpha₁-proteinase inhibitor, can cause emphysema.

Talecris Responds to U.S. Federal Trade Commission Filing

Thu, 28 May 2009 9:00:00 EST

Talecris Biotherapeutics, Inc. yesterday was informed that the U.S. Federal Trade Commission (FTC) would file an administrative complaint challenging CSL’s proposed acquisition of Talecris and a complaint in U.S. Federal District Court to enjoin the transaction.

Talecris Presents New Data from Phase III Studies

Mon, 18 May 2009 9:00:00 EST

Talecris Biotherapeutics today presented results from two phase III studies assessing the safety, tolerability and pharmacokinetic comparability of a more concentrated formulation of Prolastin(R) (Alpha1-Proteinase Inhibitor [Human]) produced via a modification of the current manufacturing process that incorporates technological changes.

New Publication of Landmark Study Demonstrates

Thu, 23 April 2009 9:00:00 EST

RESEARCH TRIANGLE PARK, N.C. (April 23, 2009) — Talecris Biotherapeutics, Inc. today announced the publication of the health-related quality of life results from the largest clinical trial ever conducted in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the April 14, 2009 issue of Neurology. The data demonstrate that long-term treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) improves and maintains health-related quality of life in patients with CIDP.

Talecris Names its 2009 Talents Grant Recipients

Thu, 09 February 2009 13:00:00 EST

Talecris Biotherapeutics, Inc. announced today the 2009 Talecris New Trials Support (Talents) grant recipients. The Talents program, entering its fourth year, aims to advance basic and clinical research addressing the use of intravenous immunoglobulin (IGIV) in immunological, hematological, and neurological indications. The grants support either a one- or two-year research period and include funding for salary, overheads, and direct costs. Talecris produces and markets Gamunex(R) (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified), a leading IGIV therapy.

Thrombate III Approved for Room Temperature Storage

Thu, 05 February 2009 16:00:00 EST

Talecris Biotherapeutics announced today that Thrombate III [Antithrombin III (Human)], the plasma-derived antithrombin concentrate indicated for the treatment of hereditary antithrombin deficiency, can now be stored under room temperature conditions [not to exceed 25C (77F)]. Stability data at room temperature was approved by the Food and Drug Administration, and the updated Prescribing Information for Thrombate III now reflects the new labeling.

Alpha-1 Foundation Awards Two Research Grants

Tue, 18 November 2008 09:00:00 EST

The Alpha-1 Foundation announced today that it has awarded two new research grants for projects at the University of Florida and Brandeis University. The grants were made possible through an unrestricted charitable donation from Talecris Biotherapeutics to the Alpha-1 Foundation.

Talecris Helps Patients Receive Gamunex During Lapses in Private.

Tue, 15 October 2008 09:00:00 EST

Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage.

Health Canada Grants Approval to Talecris Biotherapeutics for Gamunex.

Tue, 14 October 2008 09:00:00 EST

Talecris Biotherapeutics, Ltd., a wholly-owned subsidiary of Talecris Biotherapeutics, Inc., announced today Health Canada has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

Sub-Analysis of Phase III Study Suggests More than Single Treatment.

Tue, 23 September 2008 09:00:00 EST

A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah. The study authors concluded that “further studies in CIDP are warranted to more clearly define the duration of treatment required to achieve and maintain maximal response to IVIG therapy.”

Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve.

Tue, 23 September 2008 09:00:00 EST

Sub-analysis from a Phase III study of patients with a neurological disease, chronic inflammatory demyelinating polyneuropathy (CIDP), suggest that therapy with Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) may improve their physical and social functioning compared to placebo. Improvements in clinical symptoms also correlated with improvements in nerve function, according to the study funded by Talecris Biotherapeutics, Inc. The data were reported yesterday at the American Neurological Association meeting in Salt Lake City, Utah.

Jeffrey Modell Foundation and Talecris Expand Diagnostic Services

Thu, 18 September 2008 09:00:00 EST

The Jeffrey Modell Foundation (JMF) and Talecris Biotherapeutics, Inc. have donated $150,000 to Children’s Hospital Boston, the primary pediatric teaching affiliate of Harvard Medical School to expand clinical care and outreach for children with primary immunodeficiency (PI), the two organizations announced today.

FDA Grants Approval to Talecris Biotherapeutics for Gamunex as a Treatment for Neurological Disorder CIDP in the United States

Mon, 15 September 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Children's Medical Center

Fri, 12 September 2008 09:00:00 EST

The Jeffrey Modell Foundation (JMF) and Talecris Biotherapeutics, Inc. have donated $150,000 to Children’s Medical Center to expand clinical care and outreach for children with primary immunodeficiency (PI), the two organizations announced today.

Talecris Enters into Definitive Merger Agreement with CSL

Tue, 12 July 2008 21:00:00 EST

Talecris Biotherapeutics, Inc. (www.talecris.com) today announced that it has signed a definitive merger agreement with CSL under which CSL has agreed to acquire Talecris for $3.1 billion in cash. This amount includes net debt, which as of June 30, 2008 was approximately $1.2 billion, implying an equity value as of that date of about $1.9 billion.

Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha-1 Antitrypsin (AAT) From the European Commission

Thu, 24 July 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. (www.talecris.com) announced today that the European Commission followed an opinion of the Committee for Orphan Medicinal Products (COMP) and has granted orphan drug designation to Talecris’ alpha1 proteinase inhibitor [human] for inhalation use in the treatment of congenital Alpha1-Antitrypsin Deficiency (also known as AAT Deficiency or Alpha-1). Currently, there are no approved aerosolized treatments available for augmentation therapy for AAT Deficiency.

Talecris Biotherapeutics, Inc. Provides Business Update

Mon, 16 June 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. (www.talecris.com) disclosed today that it is on-track with the vertical integration of its plasma supply chain and that it has successfully completed a complex upgrade of its manufacturing facility located in Clayton, North Carolina, all intended to ensure increased supply of its plasma-based life-enhancing therapies to customers.

Talecris Biotherapeutics Awarded MedAssets Supply Chain Systems' Platinum Vendor Designation

Thu, 22 May 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. announced today that the company recently earned MedAssets Supply Chain Systems’ Platinum Vendor status award. The platinum level is the highest vendor designation awarded by MedAssets Supply Chain Systems, a MedAssets company. MedAssets is one of the largest U.S. group purchasing and supply chain organizations.

Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees

Wed, 14 May 2008 09:00:00 EST

Program grants $1 million to clinicians and scientists implementing novel studies with intravenous immunoglobulin therapies. The Talecris New Trials Support program (Talents), sponsored by Talecris Biotherapeutics, Inc., is now accepting applications for the 2008 research grants cycle. The Talents program, entering its third year, aims to advance basic and clinical research addressing the use of intravenous immunoglobulin (IGIV) in immunological, hematological, and neurological indications. Totaling $1 million, the grants support either a one- or two-year research period and include funding for salary, overheads, and direct costs.

FDA Grants Priority Review of Gamunex as a Treatment for Neurological Disorder CIDP

Thu, 08 May 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted a Priority Review of Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

Talecris Partners with Catalent Pharma Solutions for European Contract Manufacturing and Product Testing

Mon, 28 Apr 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. announced today that the company has entered into an exclusive agreement with Catalent Pharma Solutions to perform final release testing, packaging and labeling for all its products distributed in Europe for the next five years. This partnership designates Catalent as the primary contract manufacturer in Europe for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified), Prolastin (Alpha1-Proteinase Inhibitor [Human]) and a range of other commercial plasma products.

Talecris Biotherapeutics Awarded Manufacturing Contract to Supply Canada with Biological Therapies for the 20th Consecutive Year

Mon, 31 Mar 2008 09:00:00 EST

Talecris Biotherapeutics, Inc. announced today that the company has been selected by Canadian Blood Services and Hema-Quebec as the primary fractionator for Canadian plasma and the primary supplier of immune globulin intravenous (IGIV) during the next five years. This contract, beginning April 1, 2008, designates Talecris as the primary supplier of immune globulin intravenous (IGIV) through its product Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified), and a range of other commercial plasma products.